Literature DB >> 2013215

Ceftibuten and bactericidal kinetics. Comparative in vitro activity against Enterobacteriaceae producing extended spectrum beta-lactamases.

A Bauernfeind1.   

Abstract

Ceftibuten, compared to cefixime, cefetamet, cefpodoxime, loracarbef, cefprozil, cefuroxime, cefaclor, and cefadroxil, was the most active oral cephalosporin derivative against Enterobacteriaceae producing plasmid-encoded broad spectrum beta-lactamases. In a pharmacodynamic model, ceftibuten was bactericidal for Haemophilus influenzae and Streptococcus pneumoniae at concentrations simulating human serum levels following 200 mg, p.o., b.i.d.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2013215     DOI: 10.1016/0732-8893(91)90095-w

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  8 in total

1.  [Antibacterial activity and beta-lactamase stability of eleven oral cephalosporins].

Authors:  A Bauernfeind; R Jungwirth; S Schweighart; M Theopold
Journal:  Infection       Date:  1990       Impact factor: 3.553

2.  Ceftibuten concentrations in human tonsillar tissue.

Authors:  F Scaglione; J P Pintucci; G Demartini; S Dugnani
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-12       Impact factor: 3.267

3.  Multiple-dose pharmacokinetics of ceftibuten in healthy volunteers.

Authors:  C Lin; E Radwanski; M Affrime; M N Cayen
Journal:  Antimicrob Agents Chemother       Date:  1995-02       Impact factor: 5.191

4.  Pharmacokinetics and dose proportionality of ceftibuten in men.

Authors:  C Lin; J Lim; E Radwanski; A Marco; M Affrime
Journal:  Antimicrob Agents Chemother       Date:  1995-02       Impact factor: 5.191

5.  Randomized comparison of once-daily ceftibuten and twice-daily clarithromycin in the treatment of acute exacerbation of chronic bronchitis.

Authors:  W Ziering; P McElvaine
Journal:  Infection       Date:  1998 Jan-Feb       Impact factor: 3.553

Review 6.  Loracarbef. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  R N Brogden; D McTavish
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

Review 7.  Ceftibuten pharmacokinetics and pharmacodynamics. Focus on paediatric use.

Authors:  G L Kearns; R A Young
Journal:  Clin Pharmacokinet       Date:  1994-03       Impact factor: 6.447

Review 8.  Ceftibuten. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy.

Authors:  L R Wiseman; J A Balfour
Journal:  Drugs       Date:  1994-05       Impact factor: 9.546

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.